Bionaut Labs is a technology company.
Bionaut Labs has raised $63.0M across 2 funding rounds.
Bionaut Labs has raised $63.0M in total across 2 funding rounds.
Bionaut Labs has raised $63.0M in total across 2 funding rounds.
Bionaut Labs's investors include Arkitekt Ventures, Compound, Deep Valley Labs, Great Wave Ventures, Harmonix Fund, Industrifonden, Khosla Ventures, Kleiner Perkins, Hans Tung, Prime Movers Lab, Katie Gray, Kevin Colas.
Bionaut Labs is a privately held medical-technology company developing remote‑controlled, microscale robots (“Bionauts”) to deliver therapeutics and sense disease in hard‑to‑reach parts of the body—with an initial focus on central nervous system (CNS) indications such as brain tumours and pediatric neurosurgical conditions[1][2].
High‑Level Overview
Bionaut builds microscale, magnetically actuated robots and an associated platform to transport and release biologics, nucleic acids or small molecules locally inside the body, aiming to increase efficacy and reduce systemic side effects versus conventional delivery methods[1][3].
Their customers and collaborators are hospitals, neurosurgeons and biopharma partners seeking precise local delivery for high‑value CNS indications and other anatomically challenging targets[2][5].
The company addresses the problem that the blood–brain barrier and anatomical inaccessibility limit therapeutic options for many brain disorders by enabling minimally invasive access and localized dosing at millimeter scale[2][3].
Bionaut has demonstrated preclinical large‑animal safety and advanced toward human trials and regulatory designations, signaling early clinical momentum and partnerships with major centers such as Mayo Clinic and Boston Children’s Hospital[2][5].
Origin Story
Bionaut Labs was founded in 2016 by a team of engineers, scientists and clinicians aiming to apply micro‑robotics to medicine[5].
Founders combined backgrounds in micro‑robotics, biomedical engineering and clinical neurosurgery to create a new delivery modality after recognizing that many CNS diseases remain untreatable due to access and delivery constraints; the idea matured through preclinical work and subsequent collaborations with leading hospitals and investors[5][2].
Early pivotal moments include successful preclinical safety demonstrations in large animals and obtaining U.S. FDA accelerated designations (Humanitarian Use Device and Orphan Drug designations for select CNS indications), which helped validate the approach and accelerate clinical planning[2][5].
Core Differentiators
Role in the Broader Tech Landscape
Bionaut sits at the intersection of micro‑robotics, precision drug delivery and neurotechnology—trends driven by demand for targeted CNS therapies, advances in magnetic actuation and growing biopharma interest in delivery platforms that improve therapeutic indices[1][2].
Timing matters because the CNS therapeutic market is large and many novel modalities (gene, cell, biologic therapies) require improved local delivery to reach full potential, creating market pull for technologies that overcome the blood–brain barrier and anatomical barriers[2][3].
Macro forces in their favor include rising R&D investment in CNS therapeutics, regulatory pathways that can accelerate devices addressing unmet pediatric and oncologic needs, and increasing hospital interest in minimally invasive alternatives[2][5].
By enabling new ways to deliver and monitor therapies, Bionaut could influence clinical trial design, partnership models between device companies and biopharma, and the broader neurosurgical toolkit for treating previously inoperable lesions[2][6].
Quick Take & Future Outlook
Near term, expect Bionaut to advance toward and initiate human clinical trials in selected CNS indications, deepen partnerships with leading hospitals and biopharma companies, and continue to build preclinical evidence for additional indications such as neurodegeneration, epilepsy, stroke and chronic pain[2][5][6].
Medium term, success in early clinical studies could validate the micro‑robotic delivery modality and unlock broader licensing or co‑development deals with pharmaceutical companies that need precise intracranial delivery for high‑value therapeutics[2][6].
Key risks and determinants include clinical safety and efficacy in humans, regulatory outcomes, manufacturability and cost‑effective scale‑up of microscale robots, and competition from other localized delivery technologies[2][1].
If Bionaut clears these hurdles, its influence could expand from niche neurosurgical uses to a platform role across multiple specialties—fulfilling its stated goal of “treating localized disease, locally.”[3]
Bionaut Labs has raised $63.0M across 2 funding rounds. Most recently, it raised $43.0M Series B in November 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2022 | $43.0M Series B | Arkitekt Ventures, Compound, Deep Valley Labs, Great Wave Ventures, Harmonix Fund, Industrifonden, Khosla Ventures, Kleiner Perkins, Hans Tung, Prime Movers Lab, Katie Gray, Kevin Colas, Trae Vassallo | |
| Mar 1, 2021 | $20.0M Series A | Deep Valley Labs, Harmonix Fund, Industrifonden, Khosla Ventures, Hans Tung, Prime Movers Lab, Katie Gray, Kevin Colas, Trae Vassallo |